The eternal story about Pigmalion and Galateya in the poem Teogonija by Michael Gofajzen

Анастасия Зезюлевич, ГродноAntique myth about Pigmalione and Galateee is interpreted in M. Gofajzen’s poem Teogonija. The eternal plot is transformed in the tideway of postmodernist tendencies. The invariant is exposed to a reduction (the motive of love of the artist and the statue which was created by him disappears) and a inversion – as a result of the creation certificate revived Galatea dies and leaves the world which is created by Pygmalion, but exchange she has an opportunity of eternal life in the uncountable worlds of addressees of art under condition of successful communicative interaction between the creator and the recipient. The artist who has given freedom to the product cannot influence its destiny and should continue creative activity. Thus the author assimilates to God-founder who creates own world by the Universe example. Interpretation of an antique plot in the postmodernist text shows the aesthetic complexities accompanying creative process, and confirms the new status of the Creator, removing the thesis about “Death of the Author” in its traditional [email protected]

Determining blood cell size using microfluidic hydrodynamics

Microfluidic flow cytometers currently analyze far fewer parameters than conventional flow cytometry or fluorescence activated cell sorting (FACS) in order to minimize cost and complexity. There is a need for microfluidic devices that analyze more and or new cell parameters with compact and minimal means. Here we show a new and explicitly microfluidic parameter, “hydrodynamic” cell size, and compare it to forward scatter in conventional flow cytometry. The hydrodynamic size of cells is determined by the degree of lateral displacement experienced while traveling through a 1.2-mm-wide non-clogging array of micro-fabricated obstacles. We show comparable size resolution between the microfluidic device and forward scatter in conventional flow cytometry and without the need to lyse red blood cells. We use the device to differentiate healthy lymphocytes from malignant lymphocytes by size alone and we use the device to detect increased numbers of activated lymphocytes in blood as a result of exposure to staphylococcal enterotoxin B (SEB), a potential bioterror agent. Together the results demonstrate a microfluidic device that performs some of the measurement and separation tasks of a flow cytometer but at a potentially lower cost and complexity.6 page(s

Microfluidic device for label-free measurement of platelet activation

In this work we demonstrate a new microfluidic method for the rapid assessment of platelet size and morphology in whole blood. The device continuously fractionates particles according to size by displacing them perpendicularly to the fluid flow direction in a micro-fabricated post array. Whole blood, labeled with the fluorescent, platelet specific, antibody PE-anti-CD41, was run through the device and the positions of fluorescent objects noted as they exited the array. From this, histograms of platelet size were created which show marked increases in size after exposure to thrombin or a temperature of 4 ◦C. We infer that the well known morphological changes that occur during activation are causing the observed increase in size.7 page(s

Neutrophil stunning by metoprolol reduces infarct size

The beta 1-adrenergic-receptor (ADRB1) antagonist metoprolol reduces infarct size in acute myocardial infarction (AMI) patients. The prevailing view has been that metoprolol acts mainly on cardiomyocytes. Here, we demonstrate that metoprolol reduces reperfusion injury by targeting the haematopoietic compartment. Metoprolol inhibits neutrophil migration in an ADRB1-dependent manner. Metoprolol acts during early phases of neutrophil recruitment by impairing structural and functional rearrangements needed for productive engagement of circulating platelets, resulting in erratic intravascular dynamics and blunted inflammation. Depletion of neutrophils, ablation of Adrb1 in haematopoietic cells, or blockade of PSGL-1, the receptor involved in neutrophil-platelet interactions, fully abrogated metoprolol's infarct-limiting effects. The association between neutrophil count and microvascular obstruction is abolished in metoprolol-treated AMI patients. Metoprolol inhibits neutrophil-platelet interactions in AMI patients by targeting neutrophils. Identification of the relevant role of ADRB1 in haematopoietic cells during acute injury and the protective role upon its modulation offers potential for developing new therapeutic strategies.European Regional Development Fund (ERDF/FEDER) PI10/02268 PI13/01979 RD12/0042/0054ERDF/FEDER SAF2015-65607-RFundacio La Marato-TV3 120/C/2015-20153032Severo Ochoa Center of Excellence (MINECO) SEV-2015-0505Pro-CNIC FoundationSpanish Ministry of Economy and Competitiveness (MINECO)Fundacion Interhospitalaria de Investigacion Cardiovascular (FIC)12.353 JCR (2017) Q1, 3/64 Multidisciplinary SciencesUE